Abstract
Pathogenic microorganisms, particularly pathogenic bacteria that cause debilitating diseases, are considered a threat for human health and well-being. Infectious diseases are rampant, particularly in developing countries. However, there are many other deadly diseases, such as cancer, diabetes, cardiac malfunction, etc., that account for significant loss of life and trauma in our society. In this article, I try to describe the role certain bacterial pathogens with long term residence in the human body can play in providing us with our next generation anticancer and other drugs, demonstrating that a certain amount of good can come out of such bacterial pathogens as well.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen K (2011) mTOR as a multifunctional therapeutic target in HIV infection. Drug Discov Today 16:715–721
Fialho AM, Chakrabarty AM (2012) Patent controversies and court cases: Cancer diagnosis, therapy and prevention. Cancer Biol Ther 13:1229–1234
Avner BS, Fialho AM, Chakrabarty AM (2012) Overcoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual framework. Bioeng Bugs 3:262–270
Bernardes N, Chakrabarty AM, Fialho AM (2013) Engineering of bacterial strains and their products for cancer therapy. Appl Microbiol Biotechnol. doi:10.1007/s00253-013-4926-6
Fialho AM, Chakrabarty AM (eds) (2010) Emerging cancer therapy: microbial approaches and biotechnological tools. Wiley, Hoboken
Fialho AM, Chakrabarty AM (2010) Promiscuous anticancer drugs from pathogenic bacteria: rational versus intelligent drug design. In: Fialho AM, Chakrabarty AM (eds) Emerging cancer therapy: microbial approaches and biotechnological tools. Wiley, Hoboken, pp 181–198
Das Gupta TK, Chakrabarty AM (2009) Compositions and methods to prevent cancer with cupredoxins. US patent 7,618,939, 17 Nov 2009
Richards JM, Warso MA, Mehta D, Christov K, Schaeffer CM, Yamada T, Beattie CW, Bressler LR, Das Gupta TK (2011) A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. J Clin Oncol 29:2511 (abstract)
Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C et al (2013) A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer. doi:10.1038/bjc.2013.74
Hong CS, Yamada T, Hashimoto W, Fialho AM, Das Gupta, TK, Chakrabarty AM (2006) Disrupting the entry barrier and attacking brain tumors: the role of the Neisseria H.8 epitope and the Laz protein. Cell Cycle 5:1633–1641
Hong CS, Yamada T, Fialho AM, Das Gupta, TK, Chakrabarty AM (2010) Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof. US patent 7,807,183, 5 Oct 2010
Fialho AM, Salunkhe P, Manna S, Mahali S, Chakrabarty AM (2012) Glioblastoma multiforme: novel therapeutic approaches. ISRN Neurology: 642345; PMID: 22462021. doi: 10.5402/2012/642345
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer India
About this paper
Cite this paper
Chakrabarty, A.M. (2014). Microbial Pathogenicity: A New Approach to Drug Development. In: Adhikari, R., Thapa, S. (eds) Infectious Diseases and Nanomedicine II. Advances in Experimental Medicine and Biology, vol 808. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1774-9_4
Download citation
DOI: https://doi.org/10.1007/978-81-322-1774-9_4
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-1773-2
Online ISBN: 978-81-322-1774-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)